Condition
Stargardt-like Macular Dystrophy
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07425574Recruiting
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
NCT07734064Phase 1Not Yet Recruiting
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
NCT04591483RecruitingPrimary
Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4
Showing all 3 trials